Sawyers C L
Howard Hughes Medical Institute, Department of Medicine, UCLA, Los Angeles, California 90095, USA.
Cold Spring Harb Symp Quant Biol. 2005;70:479-82. doi: 10.1101/sqb.2005.70.034.
The success of kinase inhibitor therapy in chronic myeloid leukemia (CML) has validated the long-held thesis in the cancer research community that a precise molecular understanding of cancer can directly affect cancer therapy. Now that several years have passed since the approval of imatinib/Gleevec for CML treatment, we have a greater appreciation for the challenges involved in effectively deploying these agents in the clinic. In this paper, I review recent events in the treatment of CML and highlight early applications of kinase inhibitor therapy to other diseases such as glioblastoma. I conclude with a vision that it may be possible, through analysis of tumor proteins secreted into serum, to track distinct molecular features of various cancers in order to select appropriate molecularly targeted therapy and measure treatment response. This new science of cancer biomarkers could radically transform the conduct of clinical trials and speed the evaluation of new molecularly targeted agents.
激酶抑制剂疗法在慢性粒细胞白血病（CML）治疗中的成功，证实了癌症研究界长期以来的一个观点，即对癌症进行精确的分子层面理解能够直接影响癌症治疗。自伊马替尼/格列卫获批用于CML治疗至今已有数年，我们对在临床中有效应用这些药物所涉及的挑战有了更深刻的认识。在本文中，我回顾了CML治疗方面的近期进展，并着重介绍了激酶抑制剂疗法在其他疾病如胶质母细胞瘤中的早期应用。我的结论是，通过分析分泌到血清中的肿瘤蛋白，有可能追踪各种癌症的独特分子特征，从而选择合适的分子靶向疗法并评估治疗反应。这种癌症生物标志物的新科学可能会彻底改变临床试验的开展方式，并加快对新型分子靶向药物的评估。
